- Home
- IVP vs PTIX Comparison
IVP vs PTIX Comparison
Compare IVP & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- PTIX
- Stock Information
- Founded
- IVP 2020
- PTIX 1994
- Country
- IVP United States
- PTIX United States
- Employees
- IVP N/A
- PTIX N/A
- Industry
- IVP Diversified Commercial Services
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- PTIX Health Care
- Exchange
- IVP Nasdaq
- PTIX Nasdaq
- Market Cap
- IVP 3.3M
- PTIX 3.3M
- IPO Year
- IVP 2023
- PTIX 2016
- Fundamental
- Price
- IVP $1.66
- PTIX $3.83
- Analyst Decision
- IVP
- PTIX
- Analyst Count
- IVP 0
- PTIX 0
- Target Price
- IVP N/A
- PTIX N/A
- AVG Volume (30 Days)
- IVP 76.0K
- PTIX 210.6K
- Earning Date
- IVP 08-13-2025
- PTIX 08-13-2025
- Dividend Yield
- IVP N/A
- PTIX N/A
- EPS Growth
- IVP N/A
- PTIX N/A
- EPS
- IVP N/A
- PTIX N/A
- Revenue
- IVP $15,399,751.00
- PTIX N/A
- Revenue This Year
- IVP N/A
- PTIX N/A
- Revenue Next Year
- IVP N/A
- PTIX N/A
- P/E Ratio
- IVP N/A
- PTIX N/A
- Revenue Growth
- IVP N/A
- PTIX N/A
- 52 Week Low
- IVP $1.26
- PTIX $2.35
- 52 Week High
- IVP $401.50
- PTIX $15.54
- Technical
- Relative Strength Index (RSI)
- IVP 46.82
- PTIX 53.21
- Support Level
- IVP $1.51
- PTIX $3.55
- Resistance Level
- IVP $1.76
- PTIX $3.97
- Average True Range (ATR)
- IVP 0.13
- PTIX 0.23
- MACD
- IVP -0.02
- PTIX 0.04
- Stochastic Oscillator
- IVP 18.43
- PTIX 81.83
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.